Systemic Lupus Erythematosus clinical trial

Jul 22, 2026

Summary SLE is a chronic autoimmune disease affecting multiple organs, with ~936K diagnosed cases across the 7MM in 2025 and expected growth by 2036. BENLYSTA (belimumab, GSK) remains the cornerstone biologic, targeting BLyS to reduce autoreactive B cells; it expanded into lupus nephritis, pediatrics, and mu...

May 29, 2026

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can affect multiple parts of the body. In 2025, it was estimated that around 512,000 individuals in the United States were living with SLE, as per DelveInsight analysis, with new treatments for SLE urgently needed as 40% of treated SLE patien...

Oct 27, 2025

As the lupus treatment landscape undergoes major changes, Roche is entering the US lupus nephritis market with a fresh FDA approval for its long-standing blood cancer drug, GAZYVA. On October 20, 2025, Roche’s Genentech division announced that the FDA had approved GAZYVA (obinutuzumab) for use in adults with active...